Treatment of persistent and difficult-to-control asthma: Updating of anti IgE therapy;Tratamiento del asma persistente y de difícil control: Actualización de la terapia anti IgE

Revista Alergia Mexico

Volumn 58, Issue SUPPL.1, 2011, Pages 1-18

  Becerril Ángeles, Martín ^a   Pérez Chavira, Rosario ^b   Martínez Aguilar, Nora ^c,d,e  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^c Hospital Pediátrico de Coyoacan SS   (Mexico)

^d INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^e INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E;

ASTHMA; IMMUNOTHERAPY; REVIEW; HUMAN;

ASTHMA; HUMANS; IMMUNOGLOBULIN E;

EID: 84858017679     PISSN: 00025151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Global Strategy for Asthma Management and Prevention. Bethesda: GINA, 2009.
2. Bateman ED, Bousquet J, Busse WW, Clark TJ, Gul N, Gibbs M, et al. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 2008; 63:932-8. (Pubitemid 351832801)
3. Consenso Latinoamericano sobre el Asma de Difícil Control. Actualización 2008. Drugs of Today 2008;44(Suppl 3):1-43.
4. Vargas-Becerra MH. Epidemiología del asma. Rev Alerg Mex 2009;56(supl.1):S3-S9.
5. Guía de Práctica Clínica, Diagnóstico y Tratamiento del Asma en Mayores de 18 años. México: Instituto Mexicano del Seguro Social, 2009. Disponible en: http://www.imss.gob.mx/ SiteCollectionDocuments/migracion/profesionales/ GuiasClinicas/GPC-Asma.pdf. Consultado el 15 de noviembre de 2011.
6. Del Rio-Navarro B, Del Rio-Chivardi JM, Berber A, Sienra-Monge JJ, Rosas- Vargas MA, Baeza-Bacab M. Asthma prevalence in children living in north Mexico City and a comparison with other Latin American cities and world regions. Allergy Asthma Proc 2006; 27:334-340. (Pubitemid 44306263)
7. Baeza Bacab MA, Romero Tapia S, Graham Zapata LF, Albertos Alpuche NE. Incremento de la frecuencia de asma en niños escolares de Villahermosa, Tabasco, México. Rev Alerg Mex 2003; 50:208-213.
8. Sistema Nacional de Vigilancia Epidemiológica. Sistema Único Automatizado para la Vigilancia Epidemiológica en Línea. Epidemiología 2004;29 (21):1-3.
9. Martínez ANE. Guía de asma. Etiopatogenia, factores de riesgo y desencadenantes de asma. Rev Alergia Méx 2009;56(supl.1):S10- S23.
10. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. (NAEPP) Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007.
11. Global Strategy for Asthma Management and Prevention. GINA 2004.
12. Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126:926-38.
13. Payne D, Saglani S, Suri R, Hall P, Wilson N, Bush A. Asthma: beyond the guidelines. Curr Paediatr 2004; 14:336-46. (Pubitemid 38952933)
14. Remes ST, Korppi M. Asthma and atopy in schoolchildren in a defined population. Acta Paediatr 1996; 85:965-970. (Pubitemid 26273844)
15. Foucard T. Allergy and allergy-like symptoms in 1,050 medical students. Allergy 1991;46:20-26.
16. Haselkorn T, Borish L, Miller DP, Weiss ST, Wong DA, for the TENOR Study Group. High prevalence of skin test positivity in severe or difficult-to-treat asthma. J Asthma 2006; 43:745-752. (Pubitemid 46005580)
17. Gamble J, Stevenson M, McClean E, Heaney L. The prevalence of non-adherence in difficult asthma. Am J Respir Crit Care Med 2009;108:1-6.
18. Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervenA intervention to improve non-adherence in difficult to control asthma. Respir Med 2011;105:1308-15.
19. Ten Thoren C, Peterman F. Reviewing asthma and anxiety. Respir Med 2000;94:409-15.
20. Barnes N. Most difficult asthma originates primarily in adult life. Paed Respir Rev 2006;7:141-144. (Pubitemid 43840890)
21. DiMatteo MR, Sherbourne CD, Hays RD, Ordway L, Kravitz RL, McGlynn EA, et al. Physicians' characteristics influence patients' adherence to medical treatment: results from the Medical Outcomes Study. Health Psychol 1993;12:93-102.
22. Moffat M, Cleland J, van der Molen T, Price D. Sub-optimal patient and physician communication in primary care consultations: its relation to severe and difficult asthma. Prim CareRespir J 2006;15:159-165. (Pubitemid 43816357)
23. Verkleij M, Van De Griendt EJ, Kaptein AA, Van Essen-Zandvliet L, Duiverman E, Geenen R. Behavioral problems in children and adolescents with difficult-to-treat asthma. J Asthma 2011; 48:18-24.
24. Marin TJ, Chen E, Munch JA, Miller GE. Double-exposure to acute stress and chronic family stress is associated with immune changes in children with asthma. Psychosom Med 2009;71:378-384.
25. Halimi L, Vachier I, Varrin M, Godard P, Pithon G, Chanez P. Interference of psychological factors in difficult-to-control asthma. Respir Med 2007;101:154-161. (Pubitemid 44835232)
26. Saint-Pierre P, Bourdin A, Chanez P, Daures JP, Godard P. Are overweight asthmatics more difficult to control? Allergy 2006;61:79-84. (Pubitemid 43381195)
27. Varraso R, Siroux V, Maccario J, Pin I, Kauffmann F. Asthma severity is associated with body mass index and early menarche in women. Am J Respir Crit Care Med 2005;171:334-339. (Pubitemid 40223400)
28. Beuther DA, Weiss ST, Sutherland ER. Obesity and asthma. Am J Respir Crit Care Med 2006;174:112-119. (Pubitemid 44015383)
29. Shore SA, Fredberg JJ. Obesity, smooth muscle and airway hyperresponsiveness J Allergy Clin Immunol 2005;115-925-27.
30. Haselkorn T, Fish JE, Chipps BE, Miller DP, Chen H, Weiss ST. Effect of weight change on asthma-related health outcomes in patients with severe or difficult-to-treat asthma. Respir Med 2009;103:274-283.
31. van Veen IH, Brinke A, Sterk PJ, Rabe KF, Bel EH. Airway inflammation in obese and nonobese patients with difficult-to-treat asthma. Allergy 2008;63:570-574. (Pubitemid 351490394)
32. Field SK. Asthma and gastroesophageal reflux: another piece in the puzzle. Chest 2002;121:1024-1027. (Pubitemid 34280418)
33. Wong CH, Chua CJ, Liam CK, Goh KL. Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy. Aliment Pharmacol Ther 2006;23:1321-1327.
34. Beeh KM, Micke P, Ksoll M, Buhl R. Cigarette smoking, but not sensitization to alternaria, is associated with severe asthma in urban patients. J Asthma 2001;38:41-9. (Pubitemid 32246193)
35. Haselkorn T, Lee JH, Mink DR, Weiss ST. Racial disparities in asthma-related health outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2008;101:256-263.
36. Netuveli G, Hurwitz B, Levy M, et al. Ethnic variations in asthma epidemiology,morbidity and health service utilisation: systematic review and meta-analysis of epidemiological studies. Lancet 2005;364:312-17. (Pubitemid 40139108)
37. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax 2008;63(Suppl 4):iv1-iv121.
38. National Health Interview Survey. Asthma Prevalence. Health Care Use and Mortality: United State, 2002. USA: National Center for Health Statistics, 2002.
39. Hyattsville, MD: National Center for Health Statistics; 2002. Haselkorn T, Lee JH, Mink DR, Weiss ST. Racial disparities in asthma-related health outcomes in severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2008;101:256-263.
40. Consensus statement on the use of fractional exhaled nitric oxide (FENO) in the clinical management of asthma (White Paper). Denver, CO: National Jewish Health, 2009.
41. Bukstein D, Luskin AT, Brooks EA. Exhaled nitric oxide as a tool in managing and monitoring difficult-to-treat asthma. Allergy Asthma Proc 2011;32:185-192.
42. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps BE for the TENOR Study Group. Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007:62:126-133. (Pubitemid 46090293)
43. Chen H, Blanc PD, Hayden ML, Bleecker ER, Chawla A, Lee JH, for TENOR Study Group. Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma. Value Health 2008;11:231-39. (Pubitemid 351473606)
44. Navarro Merino M, Andrés Martín A, Asensio de la Cruz O, et al. Guía de diagnóstico y tratamiento del asma de control difícil en el niño. An Pediatr (Barc) 2009;71:548-67.
45. McKenzie SA, Bush A. Difficult asthma in children. Thorax 2002; 57; 915-6. (Pubitemid 35178619)
46. Zeiger RS, Bradley E. Chipps BE, Haselkorn T, Rasouliyan L, Simons ER, Fish JE, Comparison of asthma exacerbations in pediatric and adult patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2009;124:1106-08.
47. Chipps BE, Szefler SJ, Simons ER, Haselkorn T, Mink DR, Deniz Y, Lee JH, for the TENOR Study Group. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2007;119:1156-63. (Pubitemid 46654173)
48. Bukstein D, Luskin AT, Brooks EA. Exhaled nitric oxide as a tool in managing and monitoring difficult-to-treat asthma. Allergy Asthma Proc 2011;32:185-192.
49. Dweik RA, Sorkness RL, Wenzel A, et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. Am J Respir Crit Care Med 2010; 181:315-23.
50. Marchac V, Emond S, Mamou-Mani T, Le Bihan-Benjamin C, le Bourgeois M, de Blic J, Scheinmann P, Brunelle F. Thoracic CT in pediatric patients with difficult-to-treat asthma. Am J Roentgenol 2002;179:1245-52. (Pubitemid 35204382)
51. Thomson NC, Chaudhuri R, Spears M. Emerging therapies for severe asthma. BMC Medicine 2011;9:102.
52. Howarth PH, Babu KS, Arshad HS, et al. Tumor necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60:1012-18. (Pubitemid 41705469)
53. Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNFα receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind randomized, placebo controlled trial. Thorax 2008;63:584-91. (Pubitemid 351969250)
54. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am J Respir Crit Care Med 2006;174:753-62. (Pubitemid 44511656)
55. Bennett AM, Wong M, Zain A, Panayi G, Kirkham BW. Adalimumab-induced asthma. Rheumatol 2005;44:1199-1200.
56. Janssen R, Krivokuca I, Koenderman L, Lammers J-WJ. Adalimumab-induced bronchospasm: not a class effect. Thorax 2008;63:472-3. (Pubitemid 351692360)
57. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo- controlled study of tumor necrosis factor α blockade in severe persistent asthma. Am J RespirCrit Care Med 2009;179:549-58.
58. FDA: Follow-up to the June 4, 2008 early communication about the ongoing safety review of tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). Disponible en: http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm174449.html. Consultado el 15 de noviembre de 2011.
59. Botsios C. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 2005;4:162-70. (Pubitemid 40488745)
60. Furst D, Breedveld F, Kalden J, Smolen J, Burmester G, Sieper J, Emery P, Keystone E, Schiff M, Mease P, van Riel P, Fleischmann R, Weisman M, Weinblatt M. Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 2007;66:iii2-iii22. (Pubitemid 350032626)
61. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an update. Expert Opin Pharmacother 2007;8:2089-2107. (Pubitemid 47505587)
62. Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg 2007;26:6-14. (Pubitemid 46349778)
63. Coren ME, Rosenthal M, Bush A. The use of cyclosporin in corticosteroid dependent asthma. Arch Dis Child 1997;77:522-23. (Pubitemid 28016374)
64. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996;153:509-14. (Pubitemid 26051322)
65. Evans DJ, Cullinan P, Geddes DM, Walters EH, Milan SJ, Jones P. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database of Systematic Reviews 2000, Issue 4. Art. No.: CD002993. DOI: 10.1002/14651858.CD002993
66. Davies HRH R, Olson LLG, Gibson PG. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database of Systematic Reviews 1998, Issue 3. Art. No.: CD000391. DOI: 10.1002/14651858.CD000391.
67. Stempel DA, Lammert J, Mullarkey MF. Use of methotrexate in the treatment of steroid-dependent adolescent asthmatics. Ann Allergy 1991;67:346-8.
68. Backer V, Hjardem E, Karlsmark T. Treatment with mycophenolatMofetil of steroid-dependent asthma - one case of severe asthma. J Allergy 2009:1-3. doi:10.1155/2009/821013.
69. BorishL C, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107:963-70. (Pubitemid 32523334)
70. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo- controlled trial. Am J Respir Crit Care Med 1999;160:1816-23. (Pubitemid 30004681)
71. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-87.
72. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-31. (Pubitemid 47576168)
73. Leckie MJ, tenBrinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000;356:2144-8.
74. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial base- ment membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-36. (Pubitemid 38056318)
75. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:1655-9. (Pubitemid 36760679)
76. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008;8:218-30. (Pubitemid 351323290)
77. Poole JA, Meng J, Reff M, Spellman MC, Rosenwasser LJ. Anti-CD23 mono-Anti-monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 2005;116:780-8. (Pubitemid 41400542)
78. Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, et al. Daclizumab improves asthma control in patients with moderate to severe persistente asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008;178:1002-8.
79. Bousquet J, Aubier M, Sastre J, Izquierdo JL, Adler LM, Hofbauer P, Rost KD, Harnest U, Kroemer B, Albrecht A, Bredenbrçker D. Comparison of roflumilast, an oral anti-inflamatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 2006;61:72-78. (Pubitemid 43381194)
80. Jakobsson T, Croner S, Kjellman N-I M, Pettersson A, Vassella C, Bjorksten B. Sligth steroid-sparing effect of intravenous immunoglobulin in children and adolescents with moderately severe bronchial asthma. Allergy 1994;49:413-420. (Pubitemid 24180107)
81. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148-155.
82. Spector S, Katz F, Farr R. Troleandomycin: effectiveness in steroid dependent asthma and bronchitis. J Allergy Clin Immunol 1974;54:367-379.
83. Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007;356:1327-37. (Pubitemid 46513298)
84. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009;123:107-13.
85. Hsu CL, Shiung YY, Lin BL, Chang HY, Chang TW. Accumulated immune complexes of IgE and omalizumab trap allergens in an in vitro model. Int Immunopharmacol 2010;10:533-539.
86. Rabe KF, Calhoun WJ, Smith N, Jimenez P. Can anti-IgE therapy prevent airway remodeling in allergic asthma? Allergy 2011;66:1142-1151.
87. Tan RA, Corren J. Safety of omalizumab in asthma expert opinion. Drug Safety Evaluation. Downloaded from informahealtcare.com by Novartis Pharma (Active) 03/30/11.
88. Global Strategy for Asthma Management and Prevention. GINA 2010.
89. Global Strategy for Asthma Management and Prevention. GINA 2006.
90. British Guideline on the Management of Asthma. British Thoracic Society 2011.
91. Guía Española para el Manejo del Asma 2009.
92. Canadian Thoracic Society Asthma Management Continuum-2010 Consensus Summary for children six years of age and over and adults.
93. Diagnóstico y tratamiento del asma en menores de 18 años en el primer y segundo niveles de atención. México: Secretaría de Salud, 2008. Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/ CatalogoMaestro/009-GPC-Asmamenor18a/SS-009-08-EyR.pdf. Consultado el 15 de noviembre de 2011.
94. Long AA, Fish JE, Rahmaoui A, et al. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol 2009;103(3):212-19.
95. Holgate S. Biografía de omalizumab. Now Pharma Ltd 2011:1-64.
96. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16. (Pubitemid 40293346)
97. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Cin Immunol 2001;108:184-90. (Pubitemid 32735398)
98. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-8. (Pubitemid 40293345)
99. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701-8. (Pubitemid 38850344)
100. Vignola AM, Humbert M, Bousquet J, Boulet L-P, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitent allergic asthma and persistent allergic rinitis: SOLAR. Allergy 2004; 59:709-17. (Pubitemid 38850345)
101. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee C:S, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I. "Real life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respiratory Medicine 2009;103:1633-42.
102. Molimard M, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data. Respiratory Medicine 2010;104:1381-1385.
103. Korn S. Effectiveness of omalizumab in patient 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Inmunol 2010;105:313-319
104. Nopp A, Johansson SGO, Adedoyin J, Ankerst J, Palmqvist M, Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010;65:56-60.
105. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAllary M, Taylor AF, Rohane P. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab) Pediatr 2001; 108:E36.
106. Lanier B, Bridges T, Kulus M, Fowler AT, Berhane I, Fernandez Vidaurre C. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124:1210-6.
107. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-797.
108. Berger WE, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the antibody omalizumab in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91:182-8. (Pubitemid 36999479)
109. Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med 2009;103:1098-1113.
110. Costello RW, Long DA,Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011;180:637-41.